AGP Picks
View all

Carrier-free nanoparticles show promise against TNBC and metastasis

Nov. 16, 2026
By AI, Created 05:24 UTC, Nov 16, 2026, AGP -

A new study in Small describes a self-assembled nanoparticle made from curcumin, docetaxel and indocyanine green that killed triple-negative breast cancer cells while reducing the inflammation linked to metastasis. The work also points to a more selective way to manage chemotherapy-driven immune responses after surgery.

Why it matters: - Triple-negative breast cancer makes up 10% to 15% of breast cancer cases and lacks ER, PR and HER2 targets, leaving chemotherapy as the main treatment option. - Standard chemotherapy can trigger inflammation that helps cancer cells migrate, invade and spread after surgery. - The study suggests a way to preserve anti-tumor effects while limiting the inflammatory signals that can raise metastasis risk.

What happened: - Researchers published a study in Small on carrier-free ternary nanoparticles built from curcumin, docetaxel (DTX) and indocyanine green (ICG). - The nanoparticles were designed for triple-negative breast cancer treatment and post-surgical lung metastasis control. - The work used Cloud-Clone ELISA kits to measure serum TNF-α, IL-6 and IL-1β as part of the inflammation analysis.

The details: - The nanoparticle system self-assembles without added carrier materials through π-π stacking and hydrophobic interactions. - The formulation reaches a drug-loading rate of 66.7%. - Molecular simulation shows curcumin and DTX in the inner core and ICG on the shell. - ICG provides negative surface charge for colloidal stability, near-infrared fluorescence for imaging and added structural stability through π-π stacking. - The nanoparticles release little drug at physiological pH 7.4 and release more payload in acidic pH 5.0 conditions similar to lysosomes. - In cell studies, the nanoparticles produced synergistic cytotoxicity against tumor cells. - The treatment also reduced cell migration and invasion at concentrations below the IC50 value. - Western blot and immunofluorescence data showed lower phosphorylated NF-κB p65, reduced N-cadherin, Vimentin and MMP-9, and restored E-cadherin. - Free DTX treatment raised serum TNF-α, IL-6 and IL-1β in 4T1 tumor-bearing mice. - After Cur/DTX@ICG treatment, TNF-α fell to nearly baseline, while IL-6 and IL-1β remained at moderate residual levels. - In subcutaneous tumor models, the nanoparticles produced a 74.5% tumor inhibition rate. - In a post-surgical adjuvant model, the formulation achieved a 77.1% lung metastasis inhibition rate and improved survival. - Safety testing found stable body weight, normal serum biochemistry, normal hematological parameters, normal major organ histology and no detectable acute hemolysis after repeated intravenous dosing.

Between the lines: - The study frames inflammation as something to tune rather than fully block. - That matters because complete immune suppression could weaken helpful anti-tumor responses. - The cytokine data support a “selective inflammation suppression” approach: enough immune signaling remains, but the pathological surge is reduced. - The post-surgical metastasis model is more clinically relevant than studies focused only on shrinking the primary tumor.

What's next: - The researchers say the approach still needs validation beyond the 4T1 TNBC model. - They also note that ICG’s photothermal and photodynamic effects were not tested. - Further work is needed on long-term storage stability and scalable manufacturing. - Future studies will examine whether the strategy can move into neoadjuvant chemotherapy and combine with immunotherapy.

The bottom line: - The carrier-free nanoparticle design combines tumor killing, imaging and inflammation control in one platform, and it may offer a more practical route to reducing triple-negative breast cancer metastasis after surgery.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Chemicals Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Chemicals Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.